Technical Analysis for RGLS - Regulus Therapeutics Inc.
| ADX | Long-Term | Intermediate-Term | Short-Term |
|---|---|---|---|
| Strong | Down | Up | Up |
| See historical RGLS trend table... | |||
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Boomer Buy Setup | Bullish Swing Setup | 0.00% | |
| NR7 | Range Contraction | 0.00% | |
| Inside Day | Range Contraction | 0.00% | |
| Wide Bands | Range Expansion | 0.00% | |
| Wide Bands | Range Expansion | 3.01% | |
| Wide Bands | Range Expansion | -2.84% | |
| Up 3 Days in a Row | Strength | -2.84% | |
| Upper Bollinger Band Touch | Strength | -2.84% | |
| MACD Bullish Signal Line Cross | Bullish | 4.58% | |
| Inside Day | Range Contraction | 4.58% |
Get a Trading Sidekick!
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 05/09/2019
- Sector: Healthcare
- Industry: Biotechnology
Regulus Therapeutics Inc., a biopharmaceutical company, focuses on the discovery and development of drugs that target microRNAs to treat various diseases in the United States. The company utilizes its microRNA product platform to develop anti-miRs, a chemically modified single-stranded oligonucleotides. Its microRNA development candidates target miR-122 in hepatitis C virus infection; miR-21 and miR-221 in hepatocellular carcinoma; miR-21 in kidney fibrosis; miR-33 in atherosclerosis; and miR-10b in glioblastoma. The company has strategic alliances with AstraZeneca AB, GlaxoSmithKline plc, Sanofi, and Alnylam and Isis, as well as a strategic collaboration with Biogen Idec MA Inc. Regulus Therapeutics Inc. was founded in 2007 and is headquartered in San Diego, California.
Biopharmaceutical Diseases Genetics Glioblastoma Regulus Therapeutics Hepatocellular Carcinoma RNA Alnylam Pharmaceuticals Hepatitis C Virus Infection Atherosclerosis Microrna Nucleic Acids
Biopharmaceutical Diseases Genetics Glioblastoma Regulus Therapeutics Hepatocellular Carcinoma RNA Alnylam Pharmaceuticals Hepatitis C Virus Infection Atherosclerosis Microrna Nucleic Acids
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength | |||
| Summary: | Counts: 3 bullish, 1 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies. | ||
See more RGLS news...
Indicators
| Indicator | Value |
|---|---|
| 52 Week High | 9.48 |
| 52 Week Low | 0.8 |
| Average Volume | 179,543 |
| 200-Day Moving Average | 1.5873 |
| 50-Day Moving Average | 1.1527 |
| 20-Day Moving Average | 1.252 |
| 10-Day Moving Average | 1.323 |
| Average True Range | 0.1271 |
| ADX | 31.49 |
| +DI | 32.0675 |
| -DI | 13.8284 |
| Chandelier Exit (Long, 3 ATRs ) | 1.2382 |
| Chandelier Exit (Short, 3 ATRs ) | 1.4413 |
| Upper Bollinger Band | 1.4743 |
| Lower Bollinger Band | 1.0297 |
| Percent B (%b) | 0.77 |
| BandWidth | 35.511182 |
| MACD Line | 0.057 |
| MACD Signal Line | 0.0504 |
| MACD Histogram | 0.0067 |
| Fundamentals | Value |
|---|---|
| Market Cap | 142.18 Million |
| Num Shares | 104 Million |
| EPS | -1.53 |
| Price-to-Earnings (P/E) Ratio | -0.90 |
| Price-to-Sales | 450.54 |
| Price-to-Book | 2.98 |
| PEG Ratio | -0.03 |
| Dividend | 0.00 |
| Dividend Yield | 0.00% |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 1.49 | ||||
| Resistance 3 (R3) | 1.49 | 1.44 | 1.47 | ||
| Resistance 2 (R2) | 1.44 | 1.41 | 1.45 | 1.46 | |
| Resistance 1 (R1) | 1.41 | 1.39 | 1.43 | 1.41 | 1.46 |
| Pivot Point | 1.36 | 1.36 | 1.37 | 1.37 | 1.36 |
| Support 1 (S1) | 1.33 | 1.33 | 1.35 | 1.33 | 1.28 |
| Support 2 (S2) | 1.28 | 1.31 | 1.29 | 1.28 | |
| Support 3 (S3) | 1.25 | 1.28 | 1.27 | ||
| Support 4 (S4) | 1.25 |
